EP3728271A1 - Composés macrocycliques pour le traitement de maladie - Google Patents

Composés macrocycliques pour le traitement de maladie

Info

Publication number
EP3728271A1
EP3728271A1 EP18893293.3A EP18893293A EP3728271A1 EP 3728271 A1 EP3728271 A1 EP 3728271A1 EP 18893293 A EP18893293 A EP 18893293A EP 3728271 A1 EP3728271 A1 EP 3728271A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
nhs
nhc
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18893293.3A
Other languages
German (de)
English (en)
Other versions
EP3728271B1 (fr
EP3728271A4 (fr
Inventor
Evan W. ROGERS
Jingrong Jean Cui
Dayong Zhai
Han Zhang
Jane Ung
Wei Deng
Jeffrey WHITTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Priority to RS20221099A priority Critical patent/RS63787B1/sr
Priority to EP22191652.1A priority patent/EP4151641A1/fr
Priority to SI201830779T priority patent/SI3728271T1/sl
Priority to HRP20221502TT priority patent/HRP20221502T1/hr
Publication of EP3728271A1 publication Critical patent/EP3728271A1/fr
Publication of EP3728271A4 publication Critical patent/EP3728271A4/fr
Application granted granted Critical
Publication of EP3728271B1 publication Critical patent/EP3728271B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
  • RET is a receptor tyrosine kinase that was initially discovered in 1985 through transfection of NIH3T3 cells with human lymphoma DNA
  • RET is expressed with its highest levels in early embryogenesis (during which it has diverse roles in different tissues) and decreases to relatively low levels in normal adult tissues Pachnis, V., et al. Development 1993, 119, 1005-1017). RET plays a critical role in the development of enteric nervous system and kidneys during embryogenesis (Schuchardt, A. et al. Nature 1994, 367:380-383). RET activation regulates the downstream signalling pathways (RAS/MAPK/ERK, PI3K AKT, and JAK-STAT etc.), leading to cellular proliferation, migration, and differentiation (Mulligan, LM. Nat Rev Cancer. 2014, 14(3): 173-86).
  • Gain-of-function mutations of RET with constitutive activation have been found in heritable and sporadic tumors including activating point mutations within the full-length RET protein or genomic rearrangements that produce chimeric RET oncoproteins in the cytosol.
  • the heritable oncogenic RET mutations are found in multiple endocrine neoplasia type 2 (MEN2) including medullary thyroid cancer (MTC) and familial MTC with more than 80 pathogenic variants spanning RET exons 5-16 reported (Mulligan, LM. Nat Rev Cancer. 2014, 14(3): 173- 86).
  • RET M918T and RET A883F are found in 40-65% of sporadic MTC.
  • RET fusion oncoproteins have been identified in sporadic tumors.
  • the RET rearrangements are originally reported in papillary thyroid cancers (PTCs) (Grieco, M. et al. Cell. 1990, 23; 60 (4):557-63.).
  • PTCs papillary thyroid cancers
  • the resulting fusion transcripts composed of the 3’ end of RET kinase domain and the 5’ end of separate partner genes (CCDC6, NCOA4, TRIM24, TRIM33, PRKAR1A, GOLGA5, KTN1, ERC1, MBD1, and TRIM27 etc.).
  • RET fusions are identified in approximately 20% 40% of PTCs, and CCDC6-RET and NCOA4-RET are the most commonly identified RET fusions in PTCs (Drilon A, et al. Nat Rev Clin Oncol. 2017 Nov 14. doi: l0.l038/nrclinonc.20l7.l75). RET gene fusions are also found in approximately l%-2% of non-small cell lung cancer (NSCLC) (Gainor JF, Shaw AT. Oncologist. 2013, l8(7):865-75), and over 50% of RET fusions in NSCLC is KIF5B-RET, representing the most frequent RET fusion form.
  • NSCLC non-small cell lung cancer
  • RET inhibitors have relatively low response rates and short treatment duration in the treatment of NSCLC patients with KIF5B-RET fusion gene in multiple clinical trials (Drilon, A. Nat Rev Clin Oncol. 2017 Nov 14. doi: l0.l038/nrclinonc. 2017.175). It was reported that the kinesin and kinase domains of KIF5B-RET act together to establish an emergent microtubule and RAB -vesicle-dependent RET-SRC-EGFR-FGFR signaling hub (Das TK and Cagan RL Cell Rep. 2017, 20(l0):2368-2383).
  • SRC kinase The inhibition of SRC kinase will have the potential to stop the recruitment of multiple RTKs via the N terminus of the KIF5B-RET fusion protein and the oncogenic signaling to increase the therapeutic efficiency of RET inhibitors.
  • Src family tyrosine kinases regulate MTC cellular proliferation in vitro and mediate growth signals by increasing DNA synthesis and decreasing apoptosis (Liu Z, et al. J. Clin. Endocrinol. Metab. 2004, 89, 3503-3509). Therefore, a dual inhibitor of RET and SRC represents a highly desired therapeutic intervention to maximally target abnormal RET signaling in cancers.
  • the disclosure relates to a compound of the formula I
  • L is independently -C ⁇ XR 2 )- or X;
  • X is -0-, -S-, -S(O)- or -S(0) 2 -;
  • each R 1 and R 2 is independently H, deuterium, halogen, Ci -Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or mono- or bicyclic heteroaryl, -OR a , -OC(0)R a , -OC(0)R a , -OC(0)NR a R b , -OS(0)R a , -OS(0) 2 R a , -SR a , -S(0)R a , -S(0) 2 R a , -S(0)NR a R b , -S(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b ,
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -C 6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-Cio aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, -OR e , -OC(0)R e , -OC(0)NR e R f ,
  • each R a , R b , R c , R d , R e , and R f is independently selected from the group consisting of H, deuterium, Ci-C 6 alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, 5- to 7- membered heteroaryl; [018] each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH;
  • p is 1, 2, 3, or 4;
  • t is 1, 2, 3, 4, or 5;
  • the disclosure relates to a compound of the formula I
  • L is independently -C ⁇ XR 2 )- or X;
  • X is O, S, S(O) or S(0) 2 ;
  • each R 1 and R 2 is independently H, deuterium, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Ci 0 aryl, or mono- or bicyclic heteroaryl, -OR a , -OC(0)R a , -OC(0)R a , -OC(0)NR a R b , -OS(0)R a , -OS(0) 2 R a , -SR a , -S(0)R a , -S(0) 2 R a , -S(0)NR a R b , -S(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b ,
  • M is CR 3 or N
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, -OR e , -OC(0)R e , -OC(0)NR e R f ,
  • each R a , R b , R c , R d , R e , and R f is independently selected from the group consisting of H, deuterium, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, 5- to 7- membered heteroaryl;
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH;
  • p is 1, 2, 3, or 4;
  • t is 1, 2, 3, 4, or 5;
  • the disclosure relates to a compound or a pharmaceutically acceptable salt thereof, having the formula II
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • X is O, S, S(O), or S(0) 2 ;
  • each R 1 and R 2 is independently H, deuterium, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, Ce-C 10 aryl, -OR a , -SR a , -NR a R b , -C(0)OR a , -C(0)NR a R b ; wherein each hydrogen atom in Ci-Ce alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and Ce-C 10 aryl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OCi-Ce alkyl, -NH 2 , -0C(0)CI-C 6 alkyl, -0C(0)N(Ci-Ce alkyl) 2 , -0C(0)NH(Ci-
  • R 3 , R 4 , and R 5 are each independently H, fluoro, chloro, bromo, C -Ce alkyl, -OH, -CN, -OCi-Ce alkyl, -NHCi-Ce alkyl, -N(CI-C 6 alkyl) 2 or -CF 3 ;
  • R 6 is H, Ci-Ce alkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C -Ce alkyl or 3-to 7-membered heterocycloalkyl is independently optionally substituted by halogen, -OH, -CN, -OCi-C 6 alkyl, -NH 2 , -NH(C I -C 6 alkyl), -N(C I -C 6 alkyl) 2 , -C0 2 H, -C(0)0Ci-C 6 alkyl, -C(0)NH 2 , -C(0)NH(Ci-Ce alkyl), -C(0)N(Ci-Ce alkyl) 2 , C 3 -C 6 cycloalkyl, or monocyclic 5- to 7-membered heterocycloalkyl;
  • -P(0) 2 (Ci-C 6 alkyl) 2 -P(0)NH 2 , -P(0)NH(Ci-C 6 alkyl), -P(0)N(Ci-C 6 alkyl) 2 , -P(0) 2 NH 2 , -P(0) 2 NH(C I -C 6 alkyl), -P(0) 2 N(Ci-C 6 alkyl) 2 , -P(0)0H, -P(0)0Ci-C 6 alkyl, -P(0) 2 0H, -P(0) 2 0Ci-C 6 alkyl, -CN, or -N0 2 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, or Ci-Ce alkyl, wherein each hydrogen atom in Ci-C 6 alkyl is optionally substituted by a halogen, -OH, -OCi-C 6 alkyl, -0C(0)Ci-Ce alkyl, -0C(0)N(Ci-Ce alkyl) 2 , -0C(0)NH(Ci-C 6 alkyl), -0C(0)NH 2 ,
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH; and [051] n is 2 or 3.
  • the disclosure relates to a compound selected from the group consisting of
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • X is O, S, S(O), or S(0) 2 ;
  • R 1 and R 2 are each independently H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 3 -C 6 cycloalkyl, Ce-Cio aryl, -OR a , -SR a , -NR a R b , -C(0)0R a , -C(0)NR a R b ; wherein each hydrogen atom in Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and Ce-Cio aryl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OCi-Ce alkyl, -OCi-Ce alkyl(C 6 -Cio aryl), -NH 2 , -0C(0)Ci-C 6 alkyl, -0C(0)N(Ci-C 6
  • R 3 , R 4 , and R 5 are each independently H, fluoro, chloro, bromo, C 1 -Ce alkyl, -OH, -CN, -OCi-Ce alkyl, -NHCi-Ce alkyl, -N(CI-C 6 alkyl) 2 or -CF 3 ;
  • R 6 is H, Ci-Ce alkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -Ce alkyl or 3-to 7-membered heterocycloalkyl is independently optionally substituted by halogen, -OH, -CN, -OCi-C 6 alkyl, -NH 2 , -NH(C I -C 6 alkyl), -N(C I -C 6 alkyl) 2 , -C0 2 H, -C(0)OCi-C 6 alkyl, -C(0)NH 2 , -C(0)NH(Ci-Ce alkyl), -C(0)N(Ci-Ce alkyl) 2 , C 3 -C 6 cycloalkyl, or monocyclic 5- to 7-membered heterocycloalkyl;
  • -P(0) 2 (Ci-C 6 alkyl) 2 -P(0)NH 2 , -P(0)NH(Ci-Ce alkyl), -P(0)N(Ci-Ce alkyl) 2 , -P(0) 2 NH 2 , -P(0) 2 NH(CI-C 6 alkyl), -P(0) 2 N(Ci-C 6 alkyl) 2 , -P(0)0H, -P(0)0Ci-Ce alkyl, -P(0) 2 0H, -P(0) 2 0Ci-C 6 alkyl, -CN, or -N0 2 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, or Ci-Ce alkyl, wherein each hydrogen atom in Ci-C 6 alkyl is optionally substituted by a halogen, -OH, -OCi-C 6 alkyl,
  • L is independently -C ⁇ XR 2 )- or X;
  • X is -0-, -S-, -S(O)- or -S(0) 2 -;
  • each R 1 and R 2 is independently H, deuterium, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or mono- or bicyclic heteroaryl, -OR a , -OC(0)R a , -OC(0)R a , -OC(0)NR a R b , -OS(0)R a , -OS(0) 2 R a , -SR a , -S(0)R a , -S(0) 2 R a , -S(0)NR a R b , -S(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b , -OS(0)NR a R b , -OS(0) 2 NR a R b ,
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • each R 3 , R 4 , and R 5 is independently hydrogen, deuterium, halogen, -OR c , -OC(0)R c ,
  • Ci-Ce alkyl, Ci-Ce haloalkyl, -OR e , -OC(0)R e , -OC(0)NR e R f , -OC( N)NR e R f , -OS(0)R e , -
  • R 7 and R 8 combine to form a C3-C7 cycloalkyl, a 5- to 8-membered heterocycloalkyl,
  • Ce-Cio aryl, or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 3 -C 7 cycloalkyl, a 5- to 8-membered heterocycloalkyl, Ce-C i o aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, -OR e , -0C(0)R e , -0C(0)NR e R f , - OC( N)NR e R f , -0S(0)R e , -0S(0) 2 R e , -0S(0)NR e R f , -0S(0) 2 NR e R f , -SR e , -S(0)R e , -S(0) 2 R e , -S(0)NR e R f , -S(0) 2 NR e R f , -NR e R f , -NR
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -C 6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Cio aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, -OR e , -OC(0)R e , -OC(0)NR e R f ,
  • each R a , R b , R c , R d , R e , and R f is independently selected from the group consisting of H, deuterium, Ci-C 6 alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, 5- to 7- membered heteroaryl;
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH;
  • p is 1, 2, 3, or 4;
  • t is 1, 2, 3, 4, or 5;
  • L is independently -C ⁇ XR 2 )- or X;
  • X is O, S, S(O) or S(0) 2 ;
  • each R 1 and R 2 is independently H, deuterium, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Ci 0 aryl, or mono- or bicyclic heteroaryl, -OR a , -0C(0)R a , -0C(0)R a , -0C(0)NR a R b , -0S(0)R a , -0S(0) 2 R a , -SR a , -S(0)R a , -S(0) 2 R a , -S(0)NR a R b , -S(0) 2 NR a R b , -0S(0)NR a R b , -0S(0) 2 NR a
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -C 6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -Ci 0 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in Ci-Ce alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, -OR e , -OC(0)R e , -OC(0)NR e R f ,
  • each R a , R b , R c , R d , R e , and R f is independently selected from the group consisting of H, deuterium, Ci-C 6 alkyl, C 2 -Ce alkenyl, C 2 -Ce alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce-C 10 aryl, 5- to 7- membered heteroaryl;
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH;
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • X is O, S, S(O), or S(0) 2 ;
  • each R 1 and R 2 is independently H, deuterium, Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 3 -C 6 cycloalkyl, Ce-Cio aryl, -OR a , -SR a , -NR a R b , -C(0)OR a , -C(0)NR a R b ; wherein each hydrogen atom in Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and Ce-Cio aryl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OCi-Ce alkyl, -NH 2 , -OC(0)CI-C 6 alkyl, -OC(0)N(CI-C 6 alkyl) 2 , -OC(0)NH(CI-C 6 alkyl), -OC(0)NH 2
  • R 3 , R 4 , and R 5 are each independently H, fluoro, chloro, bromo, C 1 -Ce alkyl, -OH, -CN, -OCi-Ce alkyl, -NHCi-Ce alkyl, -N(CI-C 6 alkyl) 2 or -CF 3 ;
  • R 6 is H, Ci-Ce alkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -Ce alkyl or 3-to 7-membered heterocycloalkyl is independently optionally substituted by halogen, -OH, -CN, -OCi-Ce alkyl, -NH 2 , -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl) 2 , -C0 2 H, -C(0)OCi-C 6 alkyl, -C(0)NH 2 , -C(0)NH(Ci-Ce alkyl), -C(0)N(Ci-C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or monocyclic 5- to 7-membered heterocycloalkyl;
  • R 7 and R 8 combine to form a C 3 -C 7 cycloalkyl, a 5- to 8-membered heterocycloalkyl,
  • -OS(0)NH 2 -OS(0)NH(CI-C 6 alkyl), -OS(0)N(Ci-Ce alkyl) 2 , -0S(0) 2 NH 2 , -0S(0) 2 NH(Ci-C 6 alkyl), -0S(0) 2 N(Ci-C 6 alkyl) 2 , -SH, -SCi-Ce alkyl, -S(0)Ci-C 6 alkyl, -S(0) 2 Ci-C 6 alkyl,
  • -NHS(0) 2 CI-C 6 alkyl, -N(Ci-Ce alkyl)S(0) 2 Ci-C 6 alkyl, -NHS(0)NH 2 , -NHS(0)NH(Ci-C 6 alkyl), -NHS(0)N(Ci-C 6 alkyl) 2 , -N(Ci-Ce alkyl)S(0)NH 2 , -N(Ci-Ce alkyl)S(0)NH(Ci-C 6 alkyl), -N(Ci-Ce alkyl)S(0)N(Ci-Ce alkyl) 2 , -NHS(0) 2 NH 2 , -NHS(0) 2 NH(Ci-C 6 alkyl),
  • -P(0) 2 (Ci-C 6 alkyl) 2 -P(0)NH 2 , -P(0)NH(Ci-C 6 alkyl), -P(0)N(Ci-C 6 alkyl) 2 , -P(0) 2 NH 2 , -P(0) 2 NH(CI-C 6 alkyl), -P(0) 2 N(Ci-C 6 alkyl) 2 , -P(0)0H, -P(0)0Ci-C 6 alkyl, -P(0) 2 0H, -P(0) 2 0Ci-C 6 alkyl, -CN, or -N0 2 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, or Ci-C 6 alkyl, wherein each hydrogen atom in Ci-C 6 alkyl is optionally substituted by a halogen, -OH, -OCi-C 6 alkyl, -OC(0)Ci-C 6 alkyl, -OC(0)N(CI-C 6 alkyl) 2 , -OC(0)NH(CI-C 6 alkyl), -OC(0)NH 2 ,
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH;
  • n 2 or 3.
  • Ci-Ce alkyl, and R 2 is H; or R 1 is H, and R 2 is C 3 -C 7 cycloalkyl; or R 1 is C 3 -C 7 cycloalkyl, and R 2 is H; or wherein one of R 1 is Ci-C 6 alkyl, any other R 1 , when present, is H, and any R 2 , when present, is H .
  • Ci-C 6 alkyl -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl) 2 , -NHC(0)Ci-C 6 alkyl, -N(CI-C 6 alkyl)C(0)Ci-C 6 alkyl, -NHC(0)NH 2 , -NHC(0)NH(Ci-C 6 alkyl), -N(CI-C 6 alkyl)C(0)NH 2 ,
  • -N(Ci-Ce alkyl)S(0) 2 Ci-C 6 alkyl , -NHS(0)NH 2 , -NHS(0) 2 NH 2 , -N(C I -C 6 alkyl)S(0)NH 2 , -N(Ci-Ce alkyl)S(0) 2 NH 2 , -NHS(0)NH(Ci-C 6 alkyl), -NHS(0) 2 NH(Ci-C 6 alkyl),
  • M is CR 3 or N
  • M 1 is CR 4 ;
  • X is O, S, S(O), or S(0) 2 ;
  • R 1 and R 2 are each independently H, deuterium, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Ce-C 10 aryl, -OR a , -SR a , -NR a R b , -C(0)OR a , -C(0)NR a R b ; wherein each hydrogen atom in Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and Ce-C 10 aryl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OCi-Ce alkyl, -OCi-Ce alkyl(C 6 -Cio aryl), -NH 2 , -OC(0)Ci-C 6 alkyl, -OC(0)N(CI-C 6 alkyl) 2 ,
  • R 3 , R 4 , and R 5 are each independently H, fluoro, chloro, bromo, Ci-C 6 alkyl, -OH, -CN, -OCi-Ce alkyl, -NHCi-Ce alkyl, -N(CI-C 6 alkyl) 2 or -CF 3 ;
  • R 6 is H, Ci-Ce alkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in C i -Ce alkyl or 3-to 7-membered heterocycloalkyl is independently optionally substituted by halogen, -OH, -CN, -OCi-C 6 alkyl, -NH 2 , -NH(C I -C 6 alkyl), -N(C I -C 6 alkyl) 2 , -C0 2 H, -C(0)0Ci-C 6 alkyl, -C(0)NH 2 , -C(0)NH(Ci-C 6 alkyl), -C(0)N(Ci-C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or monocyclic 5- to 7-membered heterocycloalkyl;
  • -P(0) 2 (Ci-C 6 alkyl) 2 -P(0)NH 2 , -P(0)NH(Ci-C 6 alkyl), -P(0)N(Ci-C 6 alkyl) 2 , -P(0) 2 NH 2 , -P(0) 2 NH(C I -C 6 alkyl), -P(0) 2 N(Ci-C 6 alkyl) 2 , -P(0)0H, -P(0)0Ci-C 6 alkyl, -P(0) 2 0H, -P(0) 2 0Ci-C 6 alkyl, -CN, or -N0 2 ;
  • Y is O, S, NR 9 , or CR 9 R 10 ;
  • R 9 and R 10 are each independently H, deuterium, halogen, or Ci-C 6 alkyl, wherein each hydrogen atom in Ci-C 6 alkyl is optionally substituted by a halogen, -OH, -OCi-C 6 alkyl,
  • a pharmaceutical composition comprising a compound of any one of the preceding clauses, or a pharmaceutically acceptable salt thereof, and optionally at least one diluent, carrier or excipient.
  • a method of treating cancer comprising administering to a subject in need of such treatment an effective amount of at least one compound of any one of clauses 1 to 42, or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting RET or SRC comprising contacting a cell comprising one or more of such kinases with an effective amount of at least one compound of any one of clauses 1 to 42, or a pharmaceutically acceptable salt thereof, and/or with at least one pharmaceutical composition of the disclosure, wherein the contacting is in vitro, ex vivo, or in vivo.
  • Fig. 1 shows the pharmacodynamic inhibiting activity of Compound 5 on RET in RET- driven cells, specifically that Compound 5 caused the suppression of RET autophosphorylation at IC50s of around 0.3 nM in TT.
  • Fig. 2 shows the pharmacodynamic inhibiting activity of Compound 5 on RET in RET- driven cells, specifically that Compound 5 caused the suppression of RET autophosphorylation at IC50s of around 1-3 nM in Ba/F3 KIF5B-RET WT.
  • FIG. 3 shows the pharmacodynamic inhibiting activity of Compound 5 on RET in RET- driven cells, specifically that Compound 5 caused the suppression of RET autophosphorylation at IC50s of around 3-10 nM in Ba/F3 KIF5B-RET G810R.
  • Fig. 4A is a chart that shows that Compound 5 dosed at 2 mg/kg BID and 5 mg/kg BID for 27 days decreased tumor size in test mice compared to untreated control. Untreated control ( ⁇ * ⁇ ), 2 mg/kg (-*”), 5 mg/kg ( ⁇ * ⁇ ).
  • Fig. 4B is a chart that shows % weight change for test mice dosed at 2 mg/kg BID and 5 mg/kg BID for 27 days compared to untreated control. Untreated control ( ⁇ -), 2 mg/kg ( ⁇ "), 5 mg/kg ( “sir ⁇ ).
  • Fig. 5A is a chart that shows the effect of Compound 5 dosed at 1 mg/kg BID and 5 mg/kg BID for 10 days on tumor size in test mice compared to untreated control. Untreated control
  • Fig. 5B is a chart that shows % weight change for test mice dosed at 1 mg/kg BID and 5 mg/kg BID for 10 days compared to untreated control. Untreated control ( 1 mg/kg ( ⁇ * ⁇ ), 5 mg/kg ( ⁇ ).
  • Fig. 6A is a chart that shows the effect of Compound 5 dosed at 1 mg/kg BID, 5 mg/kg BID, and 10 mg/kg BID for 14 days on tumor size in test mice compared to untreated control.
  • Untreated control ( ⁇ ), 1 mg/kg (" ⁇ "), 5 mg/kg ( -A- ). 10 mg/kg ( -).
  • Fig. 6B is a chart that shows % weight change for test mice dosed at 1 mg/kg BID, 5 mg/kg BID, and 10 mg/kg BID for 14 days compared to untreated control. Untreated control (
  • Fig. 7A is a chart that shows the effect of Compound 5 dosed at 1 mg/kg BID and 5 mg/kg BID for 21 days on tumor size in test mice compared to untreated control. Untreated control
  • Fig. 7B is a chart that shows % weight change for test mice dosed at 1 mg/kg BID and 5 mg/kg BID for 21 days compared to untreated control. Untreated control ( ⁇ ), 1 mg/kg ( "* ⁇ ), 5 mg/kg (-*-).
  • alkyl includes a chain of carbon atoms, which is optionally branched and contains from 1 to 20 carbon atoms. It is to be further understood that in certain embodiments, alkyl may be advantageously of limited length, including C1-C12, C1-C10, C1-C9, Ci-C 8 , C1-C7, Ci-Ce, and C1-C4, Illustratively, such particularly limited length alkyl groups, including Ci-C 8 , Ci-C 7 , Ci-C 6 , and C1-C4, and the like may be referred to as“lower alkyl.” Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl,
  • Alkyl may be substituted or unsubstituted.
  • “alkyl” may be combined with other groups, such as those provided above, to form a functionalized alkyl.
  • the combination of an“alkyl” group, as described herein, with a “carboxy” group may be referred to as a“carboxyalkyl” group.
  • Other non-limiting examples include hydroxyalkyl, aminoalkyl, and the like.
  • alkenyl groups including C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 may be referred to as lower alkenyl.
  • Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
  • Illustrative alkenyl groups include, but are not limited to, ethenyl, l-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.
  • alkynyl includes a chain of carbon atoms, which is optionally branched, and contains from 2 to 20 carbon atoms, and also includes at least one carbon-carbon triple bond (i.e. CoC). It will be understood that in certain embodiments, alkynyl may each be advantageously of limited length, including C 2 -C 12 , C 2 -C 9 , C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 .
  • alkynyl groups including C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 may be referred to as lower alkynyl.
  • Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
  • Illustrative alkenyl groups include, but are not limited to, ethynyl, l-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, and the like.
  • aryl refers to an all-carbon monocyclic or fused-ring polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system.
  • aryl may be advantageously of limited size such as C 6 -Cio aryl.
  • Illustrative aryl groups include, but are not limited to, phenyl, naphthylenyl and anthracenyl. The aryl group may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
  • cycloalkyl refers to a 3 to 15 member all-carbon monocyclic ring, including an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic ring, or a multicyclic fused ring (a“fused” ring system means that each ring in the system shares an adjacent pair of carbon atoms with each other ring in the system) group, or a carbocyclic ring that is fused to another group such as a heterocyclic, such as ring 5- or 6-membered cycloalkyl fused to a 5- to 7- membered heterocyclic ring, where one or more of the rings may contain one or more double bonds but the cycloalkyl does not contain a completely conjugated pi-electron system.
  • cycloalkyl may be advantageously of limited size such as C 3 -C 13 , C 3 -C 9 , C 3 -C 6 and C 4 -C 6 .
  • Cycloalkyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
  • Illustrative cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, adamantyl, norbornyl, norbornenyl, 97/-fluoren-9-yl, and the like.
  • Illustrative examples of cycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
  • heterocycloalkyl refers to a monocyclic or fused ring group having in the ring(s) from 3 to 12 ring atoms, in which at least one ring atom is a heteroatom, such as nitrogen, oxygen or sulfur, the remaining ring atoms being carbon atoms.
  • Heterocycloalkyl may optionally contain 1, 2, 3 or 4 heteroatoms.
  • a heterocycloalkyl group may be fused to another group such as another heterocycloalkyl, or a heteroaryl group.
  • heterocycloalkyl groups include, but are not limited to, oxiranyl, thianaryl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4- dioxanyl, morpholinyl, l,4-dithianyl, piperazinyl, oxepanyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1, 2, 3, 4-tetrahydropyridinyl, and the like.
  • Illustrative examples of heterocycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
  • heteroaryl refers to a monocyclic or fused ring group of 5 to 12 ring atoms containing one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon atoms, and also having a completely conjugated pi-electron system. It will be understood that in certain embodiments, heteroaryl may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5- to 7-membered heteroaryl, and the like. Heteroaryl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
  • heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, tetrazolyl, triazinyl, pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and carbazoloyl, and the like.
  • Illustrative examples of heteroaryl groups shown in graphical representations include the following entities, in the form of properly bonded
  • “hydroxy” or““hydroxyl” refers to an -OH group.
  • alkoxy refers to both an -O-(alkyl) or an -O- (unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • aryloxy refers to an -O-aryl or an -O-heteroaryl group. Representative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and the like.
  • mercapto refers to an -SH group.
  • alkylthio refers to an -S-(alkyl) or an -S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
  • arylthio refers to an -S-aryl or an -S-heteroaryl group. Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like.
  • halo or“halogen” refers to fluorine, chlorine, bromine or iodine.
  • cyano refers to a -CN group.
  • oxo represents a carbonyl oxygen.
  • a cyclopentyl substituted with oxo is cyclopentanone.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • substitution is meant to occur at any valency-allowed position on the system.
  • “substituted” means that the specified group or moiety bears one, two, or three substituents.
  • “substituted” means that the specified group or moiety bears one or two substituents.
  • “substituted” means the specified group or moiety bears one substituent.
  • “optional” or“optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • “wherein each hydrogen atom in Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7- membered heterocycloalkyl, Ce-Cio aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by C 1 -Ce alkyl” means that an alkyl may be but need not be present on any of the C 1 -Ce alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, Ce-C i o aryl, or mono- or bicyclic heteroaryl by replacement of
  • “independently” means that the subsequently described event or circumstance is to be read on its own relative to other similar events or circumstances.
  • the use of“independently optionally” means that each instance of a hydrogen atom on the group may be substituted by another group, where the groups replacing each of the hydrogen atoms may be the same or different.
  • the use of “independently” means that each of the groups can be selected from the set of possibilities separate from any other group, and the groups selected in the circumstance may be the same or different.
  • the phrase“taken together with the carbon to which they are attached” or“taken together with the carbon atom to which they are attached” means that two substituents (e.g. R 1 and R 2 ) attached to the same carbon atom form the groups that are defined by the claim, such as C 3 -C 6 cycloalkyl or a 4- to 6-membered heterocycloalkyl.
  • the phrase “taken together with the carbon to which they are attached” means that when, for example, R 1 and R 2 , and the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl, then the formed ring will be attached at the same carbon atom.
  • the phrase“R 1 and R 2 taken together with the carbon to which they are attached form a C 3 -C 6 cycloalkyl” used in connection with the embodiments described herein includes fragments represented as follows:
  • the phrase“taken together with the carbons to which they are attached” or“taken together with the carbon atoms to which they are attached” means that two substituents (e.g. R 1 and R 2 ) attached to different carbon atoms form the groups that are defined by the claim, such as C3-C6 cycloalkyl or a 4- to 6-membered heterocycloalkyl.
  • the phrase“taken together with the carbons to which they are attached form a” means that when, for example, R 1 and R 2 , and the carbon atoms, which are not the same carbon atom, to which they are attached form a C3-C6 cycloalkyl, then the formed ring will be attached at different carbon atoms.
  • the phrase“R 1 and R 2 taken together with the carbons to which they are attached form a C3-C6 cycloalkyl” used in connection with the embodiments described herein includes fragments represented as follows:
  • the term“pharmaceutically acceptable salt” refers to those salts which counter ions which may be used in pharmaceuticals. See, generally, S.M. Berge, et ak, “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66, 1-19.
  • Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response.
  • a compound described herein may possess a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Such salts include:
  • acid addition salts which can be obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane sulfonic acid,
  • inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like
  • organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane sulfonic acid
  • ethanesulfonic acid p-toluenesulfonic acid
  • salicylic acid tartaric acid, citric acid, succinic acid or malonic acid and the like
  • a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
  • organic base such as ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine, and the like.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne- l,4-dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates,
  • a pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid,
  • the disclosure also relates to pharmaceutically acceptable prodrugs of the compounds of Formula I, II, III, IV or V, and treatment methods employing such pharmaceutically acceptable prodrugs.
  • prodrug means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula I, II, III, IV or V).
  • a “pharmaceutically acceptable prodrug” is a prodrug that is non- toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • the present disclosure also relates to pharmaceutically active metabolites of compounds of Formula I, II, III, IV or V, and uses of such metabolites in the methods of the disclosure.
  • a “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula I, II, III, IV or V, or salt thereof.
  • Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini et ah, J. Med. Chem. 1997, 40, 2011-2016; Shan et ah, J. Pharm.
  • Any formula depicted herein is intended to represent a compound of that structural formula as well as certain variations or forms.
  • a formula given herein is intended to include a racemic form, or one or more enantiomeric, diastereomeric, or geometric isomers, or a mixture thereof.
  • any formula given herein is intended to refer also to a hydrate, solvate, or polymorph of such a compound, or a mixture thereof.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, 36 Cl, and 125 I, respectively.
  • Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
  • Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed.
  • compounds described herein comprise a moiety of the formula wherein Z' -Z 6 and Y are defined as described herein, and the substituents on the non-aromatic ring marked by a bond and ⁇ correspond to R 7 and R 8 as described herein. In other embodiments, compounds described herein comprise a moiety of the formula
  • each of Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , and Z 6 is independently N, NH, C or CH.
  • Z 1 , Z 3 and Z 6 are N, Z 2 and Z 5 are CH, and Z 4 is C.
  • Z 1 , Z 3 and Z 6 are N, Z 2 and Z 5 are CH, Z 4 is C, and Y is O.
  • Z 1 , Z 2 and Z 6 are N, Z 5 is CH, and Z 3 and Z 4 are C. In some embodiments, Z 1 , Z 2 and Z 6 are N, Z 5 is CH, Z 3 and Z 4 are C, and Y is O. In some embodiments, Z 2 , Z 4 and Z 5 are N, Z 1 and Z 6 are CH, and Z 3 is C. In some embodiments, Z 2 , Z 4 and Z 5 are N, Z 1 and Z 6 are CH, Z 3 is C and Y is O. In some embodiments, Z 1 , Z 4 and Z 6 are N, Z 2 and Z 5 are CH, and Z 3 is C.
  • Z 1 , Z 4 and Z 6 are N, Z 2 and Z 5 are CH, Z 3 is C, and Y is O. In some embodiments, Z 2 and Z 4 are N, Z 1 , Z 5 and Z 6 are CH, and Z 3 is C. In some embodiments, Z 2 and Z 4 are N, Z 1 , Z 5 and Z 6 are CH, Z 3 is C, and Y is O.
  • compounds described herein comprise a moiety of the formula
  • compounds described herein comprise a moiety of the formula
  • compounds described herein comprise a moiety of the formula In still other embodiments, compounds described herein comprise a moiety of the formula
  • L is -C ⁇ XR 2 )-. In some embodiments, L is X. In some embodiments, when t is 1, L is -C ⁇ XR 2 )-.
  • X is -0-. In some embodiments, X is -S-. In some
  • X is -S(O)-. In some embodiments, X is -S(0) 2 . In some embodiments, when t is 1, L is not X. In some embodiments, when t is 2, 2, or 4, the L attached directly to the amide nitrogen in the macrocycle is not X.
  • each R 1 and R 2 is independently H, deuterium, halogen, Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce- C10 aryl, or mono- or bicyclic heteroaryl, -OR a , -0C(0)R a , -0C(0)R a , -0C(0)NR a R b , - 0S(0)R a , -0S(0) 2 R a , -SR a , -S(0)R a , -S(0) 2 R a , -S(0)NR a R b , -S(0) 2 NR a R b , -0S(0)NR a R b , -0S(0) 2 NR a R b , -0S(0) 2 NR a R b , -0S(0) 2
  • R 1 and R 2 are each independently H, deuterium, Ci-Ce alkyl, C 2 - Ce alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Ce-Cio aryl, -OR a , -SR a , -NR a R b , -C(0)OR a , -C(0)NR a R b ; wherein each hydrogen atom in C 1 -Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and Ce-Cio aryl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OCi-Ce alkyl, -OCi-C 6 alkyl(C 6 -Cio aryl), -NH 2 , -0C(0)Ci-C 6 alkyl, -0C(0)N
  • R 1 is H.
  • R 2 is H.
  • R 1 is C i -Ce alkyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is C3-C6 cycloalkyl. In some embodiments, R 1 is cyclopropyl. In some embodiments, R 2 is Ci-Ce alkyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is C3-C6 cycloalkyl. In some embodiments, R 2 is cyclopropyl. In some embodiments, R 1 is H and R 2 is C 1 -Ce alkyl. In some embodiments, R 1 and R 2 taken together with the carbon or carbons to which they are attached form a C3-C6 cycloalkyl. In some embodiments, R 1 and R 2 taken together with the carbon or carbons to which they are attached form a cyclopropane ring.
  • M is CR 3 . In some embodiments, M is N. In some embodiments,
  • M 1 is CR 4 .
  • each R 3 , R 4 , and R 5 are each independently H, fluoro, chloro, bromo, C 1 -Ce alkyl, -OH, -CN, -OCi-Ce alkyl, -NHCi-Ce alkyl, -N(Ci-Ce alkyl) 2 or -CF3.
  • R 3 is H, deuterium, Ci-Ce alkyl or halogen.
  • R 3 is H or F.
  • R 4 is H, deuterium, C 1 -Ce alkyl or halogen.
  • R 4 is H or Cl.
  • R 5 is F.
  • R 6 is H, C 1 -Ce alkyl or 3- to 7-membered heterocycloalkyl, wherein each hydrogen atom in Ci-Ce alkyl or 3-to 7-membered heterocycloalkyl is independently optionally substituted by halogen, -OH, -CN, -OCi-Ce alkyl, -NH2, -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl)2, - CO2H, -C(0)0Ci-C 6 alkyl, -C(0)NH 2 , -C(0)NH(Ci-C 6 alkyl), -C(0)N(Ci-C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or monocyclic 5- to 7-membered heterocycloalkyl.
  • R 7 and R 8 combine to form a C3-C7 cycloalkyl, a 5- to 8- membered heterocycloalkyl, Ce-Cio aryl, or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C3-C7 cycloalkyl, a 5- to 8-membered heterocycloalkyl, Ce-Cio aryl, or 5- to
  • 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, -OR e , -
  • R 7 and R 8 combine to form a 5- or 6-membered cycloalkyl, wherein each hydrogen atom in the 4-, 5- or 6-membered cycloalkyl is independently optionally substituted by deuterium, halogen, -OH, -CN, -OC 1 -Ce alkyl, -OCi-Ce alkyl(C 6 -Cio aryl), -NH 2 ,
  • Ci-C 6 alkyl -NH(Ci-Ce alkyl), -N(Ci-Ce alkyl) 2 , -NHC(0)Ci-C 6 alkyl, -N(Ci-Ce alkyl)C(0)Ci-C 6 alkyl, -NHC(0)NH 2 , -NHC(0)NH(Ci-C 6 alkyl), -N(Ci-Ce alkyl)C(0)NH 2 ,
  • R 7 and R 8 combine to form a tetrahydrofuran ring. In some embodiments, R 7 and R 8 combine to form a cyclopentane ring.
  • Y is -0-, -S-, -NR 9 , or -CR 9 R 10 -. In some embodiments, Y is -O- [0254]
  • R 9 and R 10 are each independently H, deuterium, halogen, Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, Ce- C10 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in C 1 -Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-Cio aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, -OR e , -0C(0)R
  • each R a , R b , R c , R d , R e , and R f is independently selected from the group consisting of H, deuterium, C 1 -Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl,
  • p is 1, 2, 3, or 4. In some embodiments, p is 1.
  • t is 1, 2, 3, 4, or 5. In some embodiments, t is 3. In some embodiments, t is 4. In some embodiments, t is 3 or 4.
  • n if present, is 1, 2, or 3. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 2 or 3.
  • compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients.
  • a pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents.
  • pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
  • compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
  • the pharmaceutical compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms.
  • compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
  • a suitable route of delivery such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
  • the compositions are formulated for intravenous or oral administration.
  • the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension.
  • the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
  • Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch polyvinyl -pyrrolidone (PVP), sodium starch glycolate,
  • microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules.
  • active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
  • Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain:
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like
  • non-aqueous vehicles e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water
  • preservatives for example, methyl or propyl p-hydroxybenzoate or sorbic acid
  • wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses range from about 1 to 1000 pg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier.
  • inventive compositions may be formulated for rectal administration as a suppository.
  • the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration ⁇
  • the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • Another mode of administering the agents of the invention may utilize a patch formulation to effect transdermal delivery.
  • “treat” or“treatment” encompass both“preventative” and “curative” treatment.“Preventative” treatment is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom. “Curative” treatment includes reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition.
  • treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying systemic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • Exemplary diseases include cancer, pain, neurological diseases, autoimmune diseases, and inflammation ⁇ Cancer includes, for example, lung cancer, colon cancer, breast cancer, prostate cancer, hepatocellular carcinoma, renal cell carcinoma, gastric and esophago-gastric cancers, glioblastoma, head and neck cancers, inflammatory myofibroblastic tumors, and anaplastic large cell lymphoma. Pain includes, for example, pain from any source or etiology, including cancer pain, pain from chemotherapeutic treatment, nerve pain, pain from injury, or other sources. Autoimmune diseases include, for example, rheumatoid arthritis, Sjogren syndrome, Type I diabetes, and lupus. Exemplary neurological diseases include Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic lateral sclerosis, and Huntington’s disease.
  • Exemplary inflammatory diseases include atherosclerosis, allergy, and inflammation from infection or injury.
  • the compounds and pharmaceutical compositions of the invention specifically target receptor tyrosine kinases, in particular RET.
  • the compounds and pharmaceutical compositions of the invention specifically target non-receptor tyrosine kinases, in particular SRC.
  • the compounds and pharmaceutical compositions of the invention specifically target receptor tyrosine kinases and non-receptor tyrosine kinases, such as RET and SRC, respectively.
  • compositions can be used to prevent, reverse, slow, or inhibit the activity of one or more of these kinases.
  • methods of treatment target cancer In preferred embodiments, methods are for treating lung cancer or non-small cell lung cancer.
  • an“effective amount” means an amount sufficient to inhibit the target protein. Measuring such target modulation may be performed by routine analytical methods such as those described below. Such modulation is useful in a variety of settings, including in vitro assays.
  • the cell is preferably a cancer cell with abnormal signaling due to upregulation of RET and/or SRC.
  • an“effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in subjects needing such treatment.
  • Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the infection, the subject’s health status, condition, and weight, and the judgment of the treating physician.
  • An exemplary dose is in the range of about from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
  • the total dosage may be given in single or divided dosage units (e.g., BID, TID, QID).
  • the dose may be adjusted for preventative or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms. Patients may also require chronic treatment on a long-term basis.
  • inventive compounds described herein may be used in pharmaceutical compositions or methods in combination with one or more additional active ingredients in the treatment of the diseases and disorders described herein.
  • Further additional active ingredients include other therapeutics or agents that mitigate adverse effects of therapies for the intended disease targets. Such combinations may serve to increase efficacy, ameliorate other disease symptoms, decrease one or more side effects, or decrease the required dose of an inventive compound.
  • the additional active ingredients may be administered in a separate pharmaceutical composition from a compound of the present invention or may be included with a compound of the present invention in a single pharmaceutical composition.
  • the additional active ingredients may be administered simultaneously with, prior to, or after administration of a compound of the present invention.
  • Combination agents include additional active ingredients are those that are known or discovered to be effective in treating the diseases and disorders described herein, including those active against another target associated with the disease.
  • compositions and formulations of the invention, as well as methods of treatment can further comprise other drugs or pharmaceuticals, e.g., other active agents useful for treating or palliative for the target diseases or related symptoms or conditions.
  • additional such agents include, but are not limited to, kinase inhibitors, such as EGFR inhibitors (e.g., erlotinib, gefitinib), Raf inhibitors (e.g., vemurafenib), VEGFR inhibitors (e.g.
  • compositions of the invention may additionally comprise one or more of such active agents, and methods of treatment may additionally comprise administering an effective amount of one or more of such active agents.
  • Step 1 To an azeotrope dried mixture of A-l-l (0.9615 g, 5.65 mmol) and A-1-1A (1.19 g, 6.78 mmol) in DCM (3.62 mL) was added PPI13 (2.22 g, 8.48 mmol) The mixture was stirred until everything dissolved. DIAD (1.83 g, 9.04 mmol, 1.78 mL) was added very slowly with mixing at 0 °C. The reaction was warmed to 25 °C and stirred for 16 hr. DCM (5 mL) and 2M NaOH solution (20 mL) were added and stirred vigorously for 4 hours.
  • Step 2 To a solution of A-l-2 (1.35 g, 4.13 mmol) in THF (8.27 mL) at 0 °C was added lithium borohydride (720.51 mg, 33.08 mmol) in small batches and the mixture was stirred for 1 hr and was removed from the cold bath. The mixture stirred at ambient temperature for 20 hr, then diluted with water (5mL) and extracted with ethyl acetate (3 x 5mL). The combined organic phase was washed with brine and dried over sodium sulfate. Flash column chromatography (ISCO, silica, 24g, ethyl acetate in hexanes) afforded A-l-3 (1.08 g, 3.60 mmol, 87.09% yield).
  • ISCO silica, 24g, ethyl acetate in hexanes
  • Step 4 A solution of ( 1.V , 2 /? ) - 2 - a m i n o c y c 1 o pe n t a n o 1 HC1 salt (69 mg, 504 pmol), Hunig’s Base (196 mg, 0.26 mL, 1.5 mmol) and A-1-4 (150.00 mg, 504 pmol) in dry MeOH (2.50 mL) was heated to 65 °C for 1 hr. The reaction was cooled to room temperature and NaBFL (38 mg, 1.0 mmol) was added. The mixture was stirred for 2 hr then quenched with water (3 mL) and stirred for 5 min.
  • Compound A-2 was prepared according to General Method A using (lR,2R)-2- aminocyclopentanol in step 4.
  • Step 1 Added K2CO3 (330.00 mg, 2.39 mmol) to A-3-1 (151 mg, 955.08 pmol) and A- 3-1A (283.27 mg, 1.19 mmol) in DMF (4.78 mL) and heated to 50 °C with stirring for 1 hr. The mixture was cooled and diluted with DCM (3 mL), filtered through a syringe filter and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 0-30% ethyl acetate in hexane) provide A-3-2 (301 mg, 954 pmol, 99% yield).
  • Step 4 A solution of ( 1.V,2/?)-2-aminocyclopentanol HC1 salt (104 mg, 0.76
  • Compound A-4 was prepared according to General Method A using (3/?,4/?)-4- aminotetrahydrofuran-3-ol in step 4.
  • Compound A-5 was prepared according to General Method A using 5-Fluoro-2- methoxynicotinaldehyde in step 4.
  • Compound A-6 was prepared according to General Method A using rac cA-tert-butyl-3- amino-4-hydroxypyrrolidine- 1 -carboxylate and 5-Fluoro-2-methoxynicotinaldehyde.
  • Step 1 To a solution of B-l (325 mg, 1.07 mmol) and A-l (408 mg, 1.07 mmol) in n- BuOH (5.3 mL) was added Hunig's base (689 mg, 5.3 mmol, 929 pL). The mixture was heated to 90 °C for 15 hr. The reaction was cooled and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 10-50% ethyl acetate in hexane) provided 1-1 (197.7 mg, 303 pmol, 28% yield).
  • Step 2 To a solution of 1-1 (36.6 mg, 48.5 pmol) in DMF (3 mL) was added KOt-Pent (1.7 M, 86 pL) in toluene. The reaction stirred at room temperature for 1.5 hours. The reaction was cooled to -20 °C and quenched with saturated NFLCl sol. (5 mL) then extracted with DCM (3 x 10 mL). Combined extracts were dried with Na 2 SC>4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 10-35% ethyl acetate in hexane) provided 1-2 (12.8 mg, 22 pmol, 46% yield).
  • Step 3 To a solution of 1-2 (12.8 mg, 22 pmol) in MeOH (3 mL) and THF (1 mL) at ambient temperature was added aqueous LiOH solution (2.0 M, 1.0 mL). The mixture was heated at 60 °C for 17 hr, cooled to -20 °C then quenched with aqueous HC1 solution (2.0 M) to acidic. The mixture was extracted with DCM (3 x 5 mL), dried with Na 2 S0 4, concentrated under reduced pressure, and dried under high vacuum. The crude material was dissolved in DCM (4 mL) followed by addition of HC1 in l,4-dioxane (4 M, 3 mL).
  • Step 1 To a solution of B-l (454 mg, 1.49 mmol) and A-5 (358 mg, 1.49 mmol) in t- BuOH (5.0 mL) was added Hunig's base (963 mg, 7.45 mmol, 1.30 mL). The mixture was heated to 105 °C for 17 hr. The reaction was cooled and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 10-40% ethyl acetate in hexane) provided 5- 1 (292 mg, 38% yield). [0309] Step 2.
  • Step 3 To a solution of 5-2 (6.2 mg, 14.5 pmol) in EtOH (4 mL) was added aqueous HC1 solution (4.0 M, 3.0 mL) in l,4-dioxane. The mixture was heated at 70 °C for 6 hours. The mixture was cooled, concentrated under reduced pressure, and dried under high vacuum to provide crude 5-3. Compound was used as is.
  • Step 4 Added K 2 C0 3 (14.0 mg, 101 pmol) to 5-3 (6.2 mg, 14.5 pmol) and A-3-1A (17 mg, 73 pmol) in DMF (250 pL) and stirred for 2 hours. The mixture was cooled and quenched with water (5 mL) then extracted with DCM (3 x 10 mL). Combined extracts were dried with Na 2 S0 4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 20-100% ethyl acetate in hexane) provide 5-4 (6.1 mg, 73% yield).
  • Step 5 To a solution of 5-4 (6.1 mg, 10.7 pmol) in MeOH (3 mL) and THF (1 mL) at ambient temperature was added aqueous LiOH solution (2.0 M, 1.0 mL). The mixture was heated at 60 °C for 16 hr, cooled to -20 °C then quenched with aqueous HC1 solution (2.0 M) to acidic. The mixture was extracted with DCM (3 x 5 mL), dried with Na 2 S0 4, concentrated under reduced pressure, and dried under high vacuum. The crude material was dissolved in DCM (4 mL) followed by addition of HC1 in l,4-dioxane (4 M, 3 mL).
  • Compound 6 was prepared according to General Method E using (/?)-3-Boc-4-methyl-2, 2-dioxo-[l,2,3]oxathiazolidine in step 4.
  • Step 1 To a solution of C-l-l (5.0 g, 28.1 mmol, 1 eq.) and C-l-2 (6.1 g, 39.3 mmol,
  • POCI3 99 g, 60 mL, 646 mmol, 23.00 eq.
  • Step 3 To a solution of C-l-4 (5.68 g, 20.4 mmol) and NH 4 Cl (5.46 g, 102 mmol) in THE (68 mL), EtOH (204 mL) and water (136 mL) at 0 °C was added Zn powder (5.34 g, 81.7 mmol). The mixture was stirred at 0 °C for 3 hours. The reaction mixture was filtered through a celite pad and the celite pad was rinsed with DCM (100 mL). The filtrate was concentrated to dryness under reduced pressure then resuspended in DCM (500 mL) dried with Na 2 S0 4 and concentrated under reduced pressure. Purification using a silica plug (50 g Si) and elution with DCM provided C-l-5 (3.17 g, 63.8% yield) as a white solid.
  • Step 4 To a solution of C-l-5 (1.74 g, 7.1 mmol) and the HC1 salt of (lS,2 ⁇ )-2- aminocyclopentanol (1.08 g, 7.8 mmol) in EtOH (14 mL) was added DIEA (4.6 g, 6.2 mL 35.6 mmol). The mixture was heated to 80 °C for 1 hour. The reaction cooled and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (40 g), 20-80% ethyl acetate in hexane) provided C-l-6 (2.13 g, 97% yield) as a white solid.
  • Step 5 To a solution of C-l-6 (1.0 g, 3.24 mmol) in DMSO (162 mL) was added CS2CO3 (9.51 g, 29 mmol). The mixture was heated to 100 °C and stirred for 91 hours. The reaction mixture was cooled and quenched with 30% brine solution (700 mL) then extracted with ethyl acetate (4 x 200 mL). Combined extracts were washed with 15% brine solution (2 x 250 mL). Brine solutions were back extracted with ethyl acetate (l x 250 mL). Organic extracts were combined and dried with brine (250 mL), Na 2 S0 4 and concentrated under reduced pressure to provide C-l (803 mg, 86% yield, 97% purity by LC/MS) as a light-yellow solid.
  • Step 1 To a solution of D-l-l (200 mg, 1.27 mmol) and D-1-1A (315 mg, 1.33 mmol) in DMF (6.3 mL) was added K2CO3 (437 mg, 3.2 mmol) The reaction was stirred for 2 hours then quenched with citric acid solution (1 M in H2O, 6 mL) was added and the mixture was vigorously stirred for 30 minutes. The mixture was extracted with DCM (3 x 10 mL) and combined organic extracts were collected and dried over Na2S0 4 , filtered and concentrated under reduced pressure and high vacuum to afforded desired product D-l-2 (theoretical yield 399 mg). Compound was used as is.
  • Step 2 To a solution of D-l-2 (399 mg (theoretical), 1.27 mmol) in dry THF (15 mL) was added LiBFL (193 mg, 8.86 mmol). The mixture was stirred for 20 hours then quenched with water (25 mL) and stirred for 5 min. The mixture was extracted with DCM (3 x 15 mL), dried with Na 2 S0 4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (24 g), 0-50% ethyl acetate in hexane) provided D-l-3 (33.2 mg, 8% yield).
  • Step 3 To a solution of D-l-3 (33.2 mg, 105 pmol) and DIPEA (67.6 mg, 91 pL, 523 pmol) in DCM (525 pL) at 0 °C was added MsCl (15 mg, 10 pL 131 pmol) dropwise. The mixture stirred at 0 °C for 1 hour. The reaction was quenched with water (3 mL) and 2M HC1 (100 pL) then extracted with DCM (3 x 5 mL). The organic phases were combined, dried over Na 2 S0 4 , and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 0-50% ethyl acetate in hexane) provided a mixture of D-l and D-1A (40.2 mg, 91% yield).
  • Step 1 D-2-1 (7 g, 45.12 mmol) and pyridine hydrochloride (20.86 g, 180.5 mmol) were mixed in a round bottom flask and heated up to l45°C and the molten mixture was stirred at l45°C for 30 min then cooled down. The mixture was diluted with H 2 0 (200 mL) and ethyl acetate (200 mL), partitioned and the aqueous layer was extracted with EA (5 x 100 mL), organic phases were combined and dried over Na 2 S0 4 , the solution was then concentrated under reduced pressure to afford desired product D-2-1 (5.19 g, 36.78 mmol, 81.51% yield) as yellow solid.
  • Step 2 To an ice-bathed mixture of compound D-2-1 (2.37 mg, 16.79 mmol) and Cs 2 C0 3 (21.88 g, 67.15 mmol in NMP (33.57 mL) was added compound A-3-1A (4 g, 16.79 mmol), the reaction was stirred at 0°C for 2 hours. The reaction was diluted with
  • Step 3 To an ice-bathed solution of compound D-2-2 (4.2 g, 14.06 mmol) in MeOH (46.88 mL) was added NaBH 4 (798.l7mg, 21.10 mmol). The reaction was stirred under 0 °C for 1 hour. The reaction was quenched with H 2 0 (100 mL) and was extracted with
  • Step 4 To a solution of D-2-3 (2.41 g, 8.02 mmol) and the DIPEA (4.15 g, 5.6 mL, 32.1 mmol) in DCM (14 mL) at 0 °C was added MsCl (1.10 g, 0.74 mL 9.62 mmol) dropwise. The mixture stirred at 0 °C for 2 hours. The was quenched with 1% HC1 solution (100 mL) and extracted with DCM (3 x 100 mL). The organic phases were combined, dried over Na 2 S0 4 , and concentrated under reduced pressure.
  • Compound D-3 was prepared according to General Method H using (/?)-3-boc-4- methyl-2,2-dioxo-[l,2,3]oxathiazolidine in step 2.
  • Step 1 To a solution of C-l (30 mg, 104 pmol) and D-l (41 mg, 104 pmol) in DMF (1 mL) was added CS2CO3 (102 mg, 312 pmol). The reaction was stirred at room temperature for 4 hours. The reaction was cooled, diluted with DCM (3 mL), filtered through a syringe filter and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 0-50% ethyl acetate in hexane) provided 7-1 (61 mg, 100% yield).
  • Step 2 Compound 7-1 was converted to 7 following the procedure used in General Method E.
  • Compound 12 was prepared according to General Method I using starting materials C-3 and D-2 in step 1.
  • Step 1 To a solution of 14-1 (1.0 g, 8.69 mmol) in dry MeOH (87 mL) was added HC1 (4.0 M, 4.3 mL, 2.0 eq.) in dioxane. The mixture was heated to 70 °C and stirred for 40 hours. The reaction mixture cooled and concentrated to dryness under reduced pressure to provide crude 14-2. The material was used as is in next step.
  • Step 2 To a solution of crude 14-2 from step 1 in THF (60 mL) was added Boc 2 0 (2.08 g, 9.54 mmol) and NaHCCL solution (1 M, 34.69 mL). The reaction was stirred for 4 hours then diluted with water (50 mL) and then extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed by brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (40 g), 0- 50% ethyl acetate in hexane) provided 14-3 (1.66 g, 83% yield).
  • Step 3 To a solution of 14-3 (1.66 g, 7.24 mmol) in THF (36 mL) at 0 °C was added LiBH 4 (789 mg, 36 mmol). The mixture was slowly warmed to room temperature and stirred for 20 hours. The reaction mixture was quenched by addition of water (20 mL) and aqueous saturated NH 4 Cl (25 mL) then extracted with ethyl acetate (3 x 50 mL). Combined extracts were dried with brine (50 mL), Na 2 S0 4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (40 g), 10-40% ethyl acetate in hexane) provide 14- 4 (1.23 g, 84% yield).
  • Step 4 To a solution of Imidazole (1.0 g, 14.9 mmol) in DCM (16 mL) at -5 °C was added SOCI2 (532 mg, 4.47 mmol, 324 pL) in DCM (5 mL) dropwise. The mixture was stirred at -5 °C for 1 hour. The mixture was cooled to -10 °C and 14-4 (0.5 g, 2.48 mmol) in DCM (4 mL) was added dropwise. The mixture was slowly warmed to 10 °C and stirred at this temperature for 2 hr. The reaction was quenched with water (10 mL) and stirred at 10 °C for 10 min.
  • Step 5 To a solution of 14-5 (294 mg, 1.19 mmol) in DCM (5.66 mL) and NaI04 (610.25 mg, 2.85 mmol) in H20 (5.66 mL) at 0 °C was added RuCL*3H 2 0 (6.2 mg, 24 pmol). The reaction was warmed to room temperature and stirred for 1 hour. The reaction was quenched with water (15 mL) then extracted with DCM (3 x 15 mL). Combined extracts were dried with brine (5 mL), Na 2 S0 4 and concentrated under reduced pressure. Flash
  • Step 6 To a solution of 5-3 (40 mg, 97 pmol) and 14-6 (32 mg, 121 pmol) in DMF (484 pL) was added CS2C03 (95 mg, 290 pmol). The reaction mixture was stirred for 1 hour then diluted with DCM (5 mL) and filtered through syringe filter then stirred with 20% citric acid solution (10 mL) for 30 min. The mixture was extracted with DCM (3 x 15 mL) and combined extracts dried with Na 2 S0 4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 10-50% ethyl acetate in hexane) provide 14-7 (45.6 mg, 79% yield).
  • Step 7 Compound 14-7 was converted to 14 following the procedure used in General Method E.
  • Step 1 To a solution of 5-3 (50 mg, 121 pmol), 15-1-1A (27.5 mg, 145 pmol) and PPI13 (41 mg, 157 pmol) in DCM (194 pL) at 0 °C was added DIAD (41 mg, 157 pmol). The mixture was warmed to room temperature and stirred for 16 hours. The reaction cooled and diluted with DCM. The solution was filtered and the filtrate was concentrated under reduced pressure. Flash column chromatography (ISCO, silica, al2g, ethyl acetate in hexanes) to afford 15-1 (58.8 mg, 83% yield)
  • Step 2 Compound 15-1 was converted to 15 following the procedure used in General Method E.
  • Step 1 To a solution of 5-3 (40 mg, 97 pmol) and 19-1-1A (23 mg, 116 pmol) in DMF (300 uL) was added K2CO3 (27 mg, 194 pmol). The mixture was mixture was stirred at room temperature for 16 hr. The reaction cooled and diluted with DCM (5 mL). The solution was filtered and the filtrate was concentrated under reduced pressure. The crude was purified by flash column chromatography (ISCO, silica, l2g, ethyl acetate in hexanes) to afford 15 (18.9 mg, 34% yield).
  • Step 2 Compound 19-1 was converted to 19 following the procedure used in General Method E.
  • Compound 30 and 31 were prepared according to General Method I using starting materials D-2A and C-4 in step 1 and separating the stereoisomers after the last step by flash column chromatography (ISCO, reverse phase C-18, 50g, acetonitrile in water with 0.035% TFA).
  • Step 1 To a solution of 32-1 (3.1 g, 34.03 mmol) and Boc anhydride (7.43 g, 34.03 mmol) in MeOH (68.05 mL) was added TEA (6.89 g, 68.05 mmol, 9.48 mL). The mixture was stirred at room temperature for 16 hr. The reaction was concentrated under reduced pressure and purified by flash column chromatography (ISCO, silica, 40g, methanol in dichloromethane) to afford 32-2 (6.36 g, 33.26 mmol, 97.75% yield).
  • Step 2. 32-2 (6.36 g, 33.26 mmol) and imidazole (4.53 g, 66.52 mmol) were dissolved in THF (110.86 mL) and TBS chloride (6.02 g, 39.91 mmol) was added. The mixture was stirred for 2 hr then diluted with water (200 mL) and extracted with DCM (3 x 200 mL). The combined organic phase was washed with brine (200mL) and dried over Na 2 S0 4 . The solution was filtered and the filtrate was concentrated under reduced pressure.
  • Step 3 To a solution of 32-3 (8.75 g, 28.64 mmol) and DIEA (11.11 g, 85.93 mmol, 14.97 mL) in DCM (95.48 mL) at 0°C was added MOM chloride (3.46 g, 42.96 mmol, 3.26 mL) slowly. The mixture was stirred for 16 hr. warming to ambient temperature. The reaction was quenched with water (100 mL) and extracted with DCM (3 x 100 mL). The combined extracts were dried over Na 2 S0 4 . The crude was purified by flash column chromatography (ISCO, silica, 80g, 0-30% ethyl acetate in hexanes) to afford 32-4 (7.44 g, 21.29 mmol, 74.31% yield).
  • Step 4 To a solution of 32-4 (7.44 g, 21.29 mmol) in THF (106.43 mL) was added TBAF Monohydrate (11.90 g, 42.57 mmol). The mixture was stirred for 1 hr. then quenched with saturated aqueous NH 4 Cl solution (10 mL) and diluted with DCM (lOOmL). The mixture was dried over Na 2 S0 4 and filtered. The filtrate was concentrated under reduced pressure and the crude was purified by flash column chromatography (ISCO, silica, 80 g, ethyl acetate in hexanes) to afford 32-5 (4.67 g, 19.85 mmol, 93.25% yield).
  • Compound 32 was prepared following General Method J from 32-5 in step 4 and 5-3 in step 6.
  • Step 1 To a solution of A-6 (255.4 mg, 748.15 umol, racemic mix) dissolved in anhydrous isopropanol (3.74 mL) at room temperature. DIEA (290.08 mg, 2.24 mmol, 390.94 uL) was added followed by C-l-5 (200.49 mg, 822.96 umol). The mixture stirred at 80 °C for 18 hr and then concentrated under reduced pressure. The crude was purified by flash column chromatography (ISCO, silica, l2g, ethyl acetate in hexanes) to afford 36-1 (142.1 mg, 259.05 umol, 34.63% yield).
  • Step 2 To a solution of 36-1 (142.1 mg, 259.05 umol) in DMSO (1.30 mL) at room temperature, CS2CO3 (168.81 mg, 518.10 umol) was added and the mixture was stirred at room temperature for 72 hr. Diluted with water (l5mL) and extracted with DCM (5mL x 5). The organic layer was back washed with water (lOmL) and brine (lOmL), then dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The crude was purified by flash column chromatography (ISCO, silica, l2g, ethyl acetate in hexanes) to afford 36-2 (78.1 mg, 147.77 umol, 57.04% yield).
  • 36-5 was converted to compounds 36 and 37 as a racemic mixture (cis) following the procedure used in General Method E. The mixture was separated by flash column
  • Compound 42 was prepared according to General Method K using rac /ran.v-tert-butyl- 3-hydroxycyclopentyl)carbamate and separating from 41 after final step by flash column chromatography (ISCO, silica, l2g, ethyl acetate in hexanes)
  • Compound 43 was prepared according to General Method M. Final product was purified by flash column chromatography (ISCO, silica, l2g, ethyl acetate in hexanes)
  • Step 1 ( 1 R, 25)-2-aminocyclopentanol, HC1 (3.6 g, 26.16 mmol) was dissolved in anhydrous MeOH (96.89 mL) and treated with strongly basic ion exchange resin (Amberlite IRN-78). 4-methoxybenzaldehyde (3.56 g, 26.16 mmol) was added and the solution was stirred and heated to 65 °C for 3 hr. The mixture was cooled to room temperature and NaBH 4 (989.68 mg, 26.16 mmol) was added. The reaction was stirred for 30 minutes, then quenched with water (50 mL) and stirred for another 30 minutes.
  • Step 2 C-5-1 (2.6 g, 11.75 mmol), C-l-5 (2.5 g, 10.26 mmol) and DIEA (4.56 g, 35.25 mmol, 6.14 mL) were dissolved in i-PA (58.75 mL). The mixture was stirred at 80 °C for 16 hr after which volatiles were removed under reduced pressure. The resulting crude was purified by flash column chromatography (ISCO, silica, 80g, 0-60% EtOAc in hexanes) to afford C-5-2 (2.1 g, 4.90 mmol, 41.72% yield).
  • Step 3 C-5-2 (2.1 g, 4.90 mmol) and CS2CO3 (6.39 g, 19.61 mmol) were dissolved in DMSO (49.01 mL) and stirred at room temperature for 3 hr. Diluted with water (500mL) and extracted with EtOAc (3xl00mL). The combined organic layer was washed with 20% brine solution (3xl00mL) and dried over Na 2 S0 4 . The crude was purified by flash chromatography (ISCO, 80, 0-60% EtOAc in hexanes) to afford C-5-3 (1.69 g, 4.14 mmol, 84.42% yield).
  • Step 1 49-1 (1.00 g, 13.50 mmol) was dissolved in THF (2.70 mL), water (2.70 mL) and methanol (21.60 mL). Ammonium chloride (1.66 g, 31.05 mmol) was added followed by sodium azide (4.39 g, 67.50 mmol). The mixture was stirred at 75 °C for 3 hr and then cooled to ambient temperature. Volume was carefully reduced under reduced pressure to a third and then diluted with DCM (50mL) and water (50mL). The layers were partitioned and the aqueous layer was extracted 2x with DCM (2x20mL). The combined organic layer was washed with brine and dried over sodium sulfate. Flash column chromatography (ISCO, 24g, silica, ethyl acetate in hexanes) gave 49-2 (450.00 mg, 3.84 mmol, 28.46% yield)
  • Step 2 49-2 (450.00 mg, 3.84 mmol) was dissolved in THF (19.20 mL) and PPh 3 (2.32 g, 8.83 mmol) was added. Stirred for 4hr and water (1.59 g, 88.32 mmol, 1.59 mL) was added and continued to stir for l6hr when hoc anhydride (1.09 g, 4.99 mmol) was added followed by sodium bicarbonate (32.26 mg, 384.00 umol). The mixture was stirred at RT for 4 hr and ethyl acetate and water were added (30 mL each).
  • Step 3 49-3 (525.86 mg, 2.75 mmol) was dissolved in DCM (4.58 mL) and MOM-C1 (332.10 mg, 4.13 mmol, 313.30 uL) was added followed by DIEA (710.82 mg, 5.50 mmol, 960.57 uL) at 0 °C. Stirred for 18 hr slowly warming to RT. Water (5mL) was added and the layers were partitioned. The aqueous layer was extracted 2x with DCM (5mL). The combined organic layer was washed with brine and dried over sodium sulfate. Salts were filtered and volatiles were carefully removed via rotary evaporation at temperatures ⁇ 30 °C to afford 49-4 (132.2 mg, 0.561 mmol, 20% yield). Used directly without further purification.
  • Compound 49 was prepared according to General Method K using 49-4 and 5-3.
  • reaction buffer 20 mM Hepes pH 7.5, 10 mM gCh, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na 3 V0 4 , 2 mM DTT, 1% DMSO.
  • Compounds were delivered into the reaction, followed ⁇ 20 minutes later by addition of a mixture of ATP (Sigma, St.
  • Human medulla thyroid carcinoma cell line TT (containing RET M918T mutation) and acute myelogenous cell line KG-l were purchased from ATCC.
  • Human colon cancer cell line KM12 (containing TPM3-TRKA) was obtained from NCI.
  • EML4-ALK gene (variant 1) was synthesized at GenScript and cloned into pCDH- CMV-MCS-EFl-Puro plasmid (System Biosciences, Inc).
  • Ba/F3-EML4-ALK wild type were generated by transducing Ba/F3 cells with lenti virus containing EML4-ALK wide type. Stable cell lines were selected by puromycin treatment, followed by IL-3 withdrawal. Briefly, 5X10 6 Ba/F3 cells were transduced with lentivirus supernatant in the presence of 8pg/mL protamine sulfate.
  • the transduced cells were subsequently selected with 1 pg/mL puromycin in the presence of IL3 -containing medium RPMI1640, plus 10% FBS. After 10-12 days of selection, the surviving cells were further selected for IL3 independent growth.
  • the KIF5B-RET gene was synthesized at GenScript and cloned into pCDH-CMV- MCS-EFl-Puro plasmid (System Biosciences, Inc). KIF5B-RET point mutation V804M was generated at GenScript by PCR and confirmed by sequencing.
  • Ba/F3-KIF5B-RET wild type and mutant were generated by transducing Ba/F3 cells with lenti virus containing KIF5B-RET wide type or mutant.
  • Stable cell lines were selected by puromycin treatment, followed by IL-3 withdrawal. Briefly, 5Xl0 6 Ba/F3 cells were transduced with lentivirus supernatant in the presence of 8pg/mL protamine sulfate. The transduced cells were subsequently selected with 1 pg/mL puromycin in the presence of IL3 -containing medium RPMI1640, plus 10% FBS. After 10-12 days of selection, the surviving cells were further selected for IL3 independent growth.
  • Protein lysates (approximately 20 pg) was resolved on 4-12% Bolt Bis-Tris precasted gels with MES running buffer (Life Technologies), transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-Rad) and detected with antibodies targeting phosphorylated RET (Y905) (Cell Signaling Technology), total RET (Cell Signaling Technology), actin (Cell Signaling Technology).
  • Antibodies were typically incubated overnight at 4 oC with gentle shake, followed by washes and incubation with the appropriate HRP-conjugated secondary antibodies. Membranes were incubated with chemiluminescent substrate for 5 min at room temperature (SuperSignal West Femto, Thermo Scientific).
  • chemiluminescent images were acquired with a C-DiGit Imaging System (LI-COR Biosciences).
  • the relative density of the chemiluminescent bands were quantified via Image Studio Digits from LICOR.
  • the half inhibitory concentration (IC50) value is calculated using non-linear regression analysis through GraphPad Prism software (GraphPad, Inc., San Diego, CA).
  • BaF3 KIF5B-RET WT and BaF3 KIF5B-RET G810R cells were cultured using standard techniques in RPMI-1640 medium (Coming, Inc) with 10% fetal bovine serum (Thermo Fisher Scientific, Inc) at 37°C in a humidified atmosphere with 5% C0 2 .
  • TT cells were cultured using standard techniques in F-12K medium (Corning, Inc) with 10% fetal bovine serum (Thermo Fisher Scientific, Inc) at 37°C in a humidified atmosphere with 5% CC
  • F-12K medium Corning, Inc
  • fetal bovine serum Thermo Fisher Scientific, Inc
  • cells were harvested and pelleted by centrifugation at 250g for 2 minutes. Cells were washed once and resuspended in serum-free medium supplemented with 50% matrigel (v/v).
  • mice Female SCID/Beige mice (5-8 weeks of age) were obtained from Charles River Laboratory and were housed in Innovive IVC disposable cages on HEPA filtered ventilated racks with ad libitum access to rodent chow and water.
  • Mice were randomized by tumor size into treatment groups when tumor volume reached about 200 mm 3 and Compound 5 was administered orally (BID) at determined doses.
  • TMV Tumor volume
  • TMV Treated Last Day of Treatment 100%* ⁇ l -[(TMV Treated Last Day of TreatmenfTMVTreated First Day of Treatment)/ (TMV Control on Last Day of Treatment-TMV Control on First Day of Treatment)] ⁇ when TMV Treated Last Day of Treatment iZ TMV Treated First Day of Treatment * In the Case of TMV Treated Last Day of Treatment ⁇ TMV Treated First Day of Treatment ⁇ , tumOT regression (REG) was calculated as 100%*(1- TMV Treated Last Day of Treatment/TMVrreated First Day of Treatment).
  • Compound 5 demonstrated the ability to induce tumor regression of 27% and 35% at the dose of 2 mg/kg BID and 5 mg/kg BID, respectively. Tumor size was reduced in 10 out 10 mice treated with Compound 5 at both dose levels. Body weight of the mice were measured on the designated days of the mice as shown in FIG. 4B. No body weight loss or overt abnormality was observed at either dose levels.
  • TMVs are lower in the groups treated with compound 5 at 1 mg/kg BID (p>0.05) and 5 mg/kg BID (p ⁇ 0.000l) compared to that of the control group as determined by two-way repeated ANOVA followed by post hoc analysis.
  • Compound 5 demonstrated the ability to inhibit tumor growth at 21% at the dose of 1 mg/kg BID.
  • Compound 5 treatment at 5 mg/kg BID resulted in a tumor regression of 63%, with tumor size reduction in 9 out 10 mice.
  • Body weight of the mice were measured on the designated days of the mice as shown in FIG. 5B. No body weight loss or overt abnormality was observed in compound 5 treatment groups.
  • mice bearing BaF3 KIF5B-RET G810R tumors were dosed with Compound 5 orally BID for 14 days (FIG. 6A).
  • the control group of mice were given vehicle only.
  • Tumor volume (TMV) was measured by caliper on the indicated days and is shown at mean ⁇ sem in FIG. 6A.
  • the mean TMVs are lower in the groups treated with compound 5 at 1 mg/kg BID (p>0.05), 5 mg/kg BID (p ⁇ 0.000l) and 10 mg/kg BID (p ⁇ 0.000l) compared to that of the control group as determined by two-way ANOVA followed by post hoc analysis.
  • Compound 5 treatment at 1 mg/mg BID inhibited tumor growth with a TGI of 22%.
  • Compound 5 treatment at 5 mg/kg BID resulted in a tumor regression of 39%, with tumor size reduction in 9 out 10 mice.
  • Compound 5 treatment at 10 mg/kg BID resulted in complete tumor regression in 9 out 9 mice.
  • Body weight of the mice were measured on the designated days of the mice as shown in FIG. 6B. No body weight loss or overt abnormality was observed in compound 5 treatment groups during the treatment period.
  • the CR1520 is a PDX model derived from a colorectal cancer patient harboring the NCOA4-RET fusion gene. Treating mice bearing CR1520 tumors with Compound 5 at 1 mg/kg BID for 21 days resulted inhibited tumor growth with a TGI of 63%, with tumors grew from 187 mm 3 to 872 mm 3 . For comparison, the tumors grew from 187 mm 3 to 2044 mm 3 in the vehicle treated group (FIG. 7A). Treating mice bearing CR1520 tumors with Compound 5 at 5 mg/kg BID for 21 days resulted a tumor regression from 187 mm 3 to 138 mm 3 , corresponding to a 26% tumor regression (FIG. 7A). No body weight loss was observed after 21 days of BID treatment with Compound 5 at 1 mg/kg BID or 5 mg/kg BID (FIG. 7B).
  • the CTG-0838 is a PDX model derived from a non-small cell lung cancer patient harboring the KIF5B-RET fusion gene.
  • Treating mice bearing CTG-0838 tumors with Compound 5 at 1 mg/kg BID and 2 mg/kg BID for 10 days resulted inhibited tumor growth with a TGI of 71% and 76%, respectively (FIG. 8A).
  • Treating mice bearing CTG-0838 tumors with Compound 5 at 5 mg/kg BID for 10 days resulted a tumor regression from 197 mm 3 to 174 mm 3 , corresponding to a 12% tumor regression (FIG. 8A).
  • No body weight loss was observed after 10 days of BID treatment with Compound 5 at the 1, 2 or 5 mg/kg BID (FIG.8B).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne certains dérivés macrocycliques, des compositions pharmaceutiques les contenant, et leurs procédés d'utilisation pour traiter la maladie, telle que le cancer.
EP18893293.3A 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement de maladies Active EP3728271B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RS20221099A RS63787B1 (sr) 2017-12-19 2018-12-18 Makrociklična jedinjenja za lečenje bolesti
EP22191652.1A EP4151641A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement du cancer
SI201830779T SI3728271T1 (sl) 2017-12-19 2018-12-18 Makrociklične spojine za zdravljenje bolezni
HRP20221502TT HRP20221502T1 (hr) 2017-12-19 2018-12-18 Makrociklički spojevi za liječenje bolesti

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13
PCT/US2018/066158 WO2019126121A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement de maladie

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP22191652.1A Division-Into EP4151641A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement du cancer
EP22191652.1A Division EP4151641A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement du cancer

Publications (3)

Publication Number Publication Date
EP3728271A1 true EP3728271A1 (fr) 2020-10-28
EP3728271A4 EP3728271A4 (fr) 2021-06-23
EP3728271B1 EP3728271B1 (fr) 2022-09-28

Family

ID=66992951

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18893293.3A Active EP3728271B1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement de maladies
EP22191652.1A Pending EP4151641A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement du cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22191652.1A Pending EP4151641A1 (fr) 2017-12-19 2018-12-18 Composés macrocycliques pour le traitement du cancer

Country Status (26)

Country Link
US (3) US10745416B2 (fr)
EP (2) EP3728271B1 (fr)
JP (2) JP7194188B2 (fr)
KR (1) KR20200101358A (fr)
CN (1) CN111511746B (fr)
AU (1) AU2018392332B2 (fr)
BR (1) BR112020012319A2 (fr)
CA (1) CA3083674A1 (fr)
CL (1) CL2020001632A1 (fr)
DK (1) DK3728271T3 (fr)
EC (1) ECSP20033467A (fr)
ES (1) ES2929467T3 (fr)
HR (1) HRP20221502T1 (fr)
HU (1) HUE060711T2 (fr)
IL (1) IL275265B2 (fr)
JO (1) JOP20200152A1 (fr)
LT (1) LT3728271T (fr)
MX (1) MX2020006490A (fr)
PH (1) PH12020550901A1 (fr)
PL (1) PL3728271T3 (fr)
PT (1) PT3728271T (fr)
RS (1) RS63787B1 (fr)
SG (1) SG11202005590PA (fr)
SI (1) SI3728271T1 (fr)
TW (1) TW201930312A (fr)
WO (1) WO2019126121A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286265B2 (en) 2017-12-19 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating disease

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073689A (ko) 2015-11-02 2018-07-02 블루프린트 메디신즈 코포레이션 Ret의 저해제
TWI803525B (zh) 2017-10-18 2023-06-01 美商英塞特公司 作為PI3K-γ 抑制劑之三級醇
EP3710438B1 (fr) 2017-12-19 2021-10-20 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison n triazole utilisés en tant qu'antagonistes de lpa
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
CN112703014A (zh) 2018-08-10 2021-04-23 缆图药品公司 Egfr突变型癌症的治疗
BR112021007679A2 (pt) 2018-10-22 2021-07-27 Esker Therapeutics, Inc inibidores de tyk2 e seus usos
WO2020257165A1 (fr) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles destinés à être utilisés dans le traitement d'une maladie
BR112021025786A2 (pt) 2019-06-19 2022-02-01 Turning Point Therapeutics Inc Polimorfos de um inibidor de quinase macrocíclico
WO2020257189A1 (fr) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles pour le traitement d'une maladie
WO2021027503A1 (fr) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 Composé tricyclique, procédé de préparation, intermédiaire et utilisation associés
MX2022006853A (es) * 2019-12-03 2022-09-19 Turning Point Therapeutics Inc Macrociclos para uso en el tratamiento de enfermedades.
US20230219978A1 (en) 2020-06-04 2023-07-13 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
WO2023060022A1 (fr) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthèse de composés macrocycliques
WO2024017380A1 (fr) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 Composé macrocyclique contenant un tricyclique et son utilisation
WO2024040131A1 (fr) * 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Inhibiteurs de pyridopyrimidine kras
JP7571173B2 (ja) 2023-02-24 2024-10-22 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690843B1 (fr) * 1993-03-25 2000-08-30 PHARMACIA & UPJOHN COMPANY Dérivés d'indole substitués par formyl ou cyano à activité dopaminergique
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2245994T3 (es) 2000-12-08 2006-02-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos macro-heterociclicos utilizados como inhibidores de quinasa.
EP2334301B1 (fr) 2008-09-08 2018-02-14 Merck Serono SA Pyrimidines macrocycliques en tant qu'inhibiteurs d'aurora kinase
ES2464461T3 (es) 2008-09-22 2014-06-02 Array Biopharma, Inc. Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
WO2010051549A1 (fr) 2008-10-31 2010-05-06 Genentech, Inc. Composés inhibiteurs de jak à la pyrazolopyrimidine et procédés
WO2011045330A1 (fr) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Inhibiteurs macrocycliques d'intégrase
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (fr) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (fr) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Composés macrocycliques et leur utilisation en tant qu'inhibiteurs de cdk8
EP2744331A4 (fr) 2011-08-19 2015-01-21 Merck Sharp & Dohme Procédés et intermédiaires pouvant être utilisés pour la préparation de macrolactames
US9090630B2 (en) 2011-09-30 2015-07-28 Oncodesign S.A. Macrocyclic FLT3 kinase inhibitors
WO2013132376A1 (fr) 2012-03-06 2013-09-12 Pfizer Inc. Dérivés macrocycliques pour le traitement de maladies prolifératives
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX345830B (es) 2012-03-09 2017-02-17 Lexicon Pharmaceuticals Inc Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP3572416B1 (fr) 2014-01-24 2022-09-21 Turning Point Therapeutics, Inc. Macrocycles de diaryle en tant que modulateurs de protéines kinases
DK3172213T3 (da) * 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
CN113354653A (zh) 2015-07-06 2021-09-07 特普医药公司 二芳基大环多晶型物及其制备方法
ES2818528T3 (es) 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
EP3415518B1 (fr) * 2016-03-03 2020-07-08 Shenzhen TargetRx, Inc. Macrocycle et composition comprenant le macrocycle
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
SG11201900163PA (en) 2016-07-28 2019-02-27 Tp Therapeutics Inc Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
TWI803525B (zh) 2017-10-18 2023-06-01 美商英塞特公司 作為PI3K-γ 抑制劑之三級醇
KR20200101358A (ko) 2017-12-19 2020-08-27 터닝 포인트 테라퓨틱스, 인크. 질병 치료용 대환식 화합물
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
EP3728270A4 (fr) * 2017-12-19 2021-06-23 Turning Point Therapeutics, Inc. Inhibiteurs macrocycliques de kinase et leur utilisation
EP3710438B1 (fr) 2017-12-19 2021-10-20 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison n triazole utilisés en tant qu'antagonistes de lpa
CN109956957B (zh) 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
EP3783000B1 (fr) 2018-04-18 2022-07-06 Hitgen Inc. Inhibiteur de kinase macrocyclique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286265B2 (en) 2017-12-19 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating disease

Also Published As

Publication number Publication date
IL275265B2 (en) 2023-07-01
KR20200101358A (ko) 2020-08-27
SI3728271T1 (sl) 2023-01-31
DK3728271T3 (da) 2022-12-19
JP2023027237A (ja) 2023-03-01
BR112020012319A2 (pt) 2020-11-24
US11286265B2 (en) 2022-03-29
PH12020550901A1 (en) 2021-05-17
RS63787B1 (sr) 2022-12-30
ECSP20033467A (es) 2020-09-30
MX2020006490A (es) 2020-08-17
JP2021506850A (ja) 2021-02-22
HRP20221502T1 (hr) 2023-03-31
EP3728271B1 (fr) 2022-09-28
US20200392160A1 (en) 2020-12-17
ES2929467T3 (es) 2022-11-29
EP4151641A1 (fr) 2023-03-22
CN111511746B (zh) 2024-01-09
WO2019126121A1 (fr) 2019-06-27
AU2018392332B2 (en) 2023-08-03
IL275265B1 (en) 2023-03-01
CN111511746A (zh) 2020-08-07
JOP20200152A1 (ar) 2022-10-30
PT3728271T (pt) 2022-10-06
US20200190110A1 (en) 2020-06-18
IL275265A (en) 2020-07-30
TW201930312A (zh) 2019-08-01
CA3083674A1 (fr) 2019-06-27
HUE060711T2 (hu) 2023-04-28
US20220306652A1 (en) 2022-09-29
EP3728271A4 (fr) 2021-06-23
LT3728271T (lt) 2022-12-12
US10745416B2 (en) 2020-08-18
CL2020001632A1 (es) 2020-11-20
JP7194188B2 (ja) 2022-12-21
SG11202005590PA (en) 2020-07-29
PL3728271T3 (pl) 2023-01-23
AU2018392332A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
AU2018392332B2 (en) Macrocyclic compounds for treating disease
AU2016287568B2 (en) Chiral diaryl macrocycles as modulators of protein kinases
US10689400B2 (en) Macrocycle kinase inhibitors
WO2019126122A1 (fr) Inhibiteurs macrocycliques de kinase et leur utilisation
US11142533B2 (en) Macrocycles for use in treating disease
CN115667239A (zh) 取代吡嗪类化合物，包含其的药物组合物及其用途
WO2020257189A1 (fr) Macrocycles pour le traitement d'une maladie
WO2020257165A1 (fr) Macrocycles destinés à être utilisés dans le traitement d'une maladie
KR20140023354A (ko) 면역 장애의 치료를 위한 치환된 인돌 유도체
OA20154A (en) Macrocyclic compounds for treating disease.
EA044905B1 (ru) Макроциклические соединения для лечения заболеваний

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20221502T

Country of ref document: HR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018041273

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0491180000

Ipc: C07D0498220000

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036156

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210521

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 498/22 20060101AFI20210517BHEP

Ipc: A61P 35/00 20060101ALI20210517BHEP

Ipc: A61K 31/5383 20060101ALI20210517BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220413

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3728271

Country of ref document: PT

Date of ref document: 20221006

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20220930

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018041273

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1521180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2929467

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221129

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20220928

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E022784

Country of ref document: EE

Effective date: 20221017

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20221215

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 40708

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20221502T

Country of ref document: HR

Payment date: 20221219

Year of fee payment: 5

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220402523

Country of ref document: GR

Effective date: 20230210

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20221502

Country of ref document: HR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E060711

Country of ref document: HU

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018041273

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220928

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230629

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1521180

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220928

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20221502

Country of ref document: HR

Payment date: 20231109

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231116

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231113

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231113

Year of fee payment: 6

Ref country code: GB

Payment date: 20231102

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20231128

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231211

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20231218

Year of fee payment: 6

Ref country code: SI

Payment date: 20231117

Year of fee payment: 6

Ref country code: SE

Payment date: 20231110

Year of fee payment: 6

Ref country code: RS

Payment date: 20231121

Year of fee payment: 6

Ref country code: RO

Payment date: 20231127

Year of fee payment: 6

Ref country code: PT

Payment date: 20231218

Year of fee payment: 6

Ref country code: NO

Payment date: 20231212

Year of fee payment: 6

Ref country code: MT

Payment date: 20231219

Year of fee payment: 6

Ref country code: LV

Payment date: 20231103

Year of fee payment: 6

Ref country code: LT

Payment date: 20231127

Year of fee payment: 6

Ref country code: IT

Payment date: 20231110

Year of fee payment: 6

Ref country code: IE

Payment date: 20231109

Year of fee payment: 6

Ref country code: HU

Payment date: 20231121

Year of fee payment: 6

Ref country code: HR

Payment date: 20231109

Year of fee payment: 6

Ref country code: FR

Payment date: 20231108

Year of fee payment: 6

Ref country code: FI

Payment date: 20231219

Year of fee payment: 6

Ref country code: EE

Payment date: 20231107

Year of fee payment: 6

Ref country code: DK

Payment date: 20231214

Year of fee payment: 6

Ref country code: DE

Payment date: 20231031

Year of fee payment: 6

Ref country code: CZ

Payment date: 20231129

Year of fee payment: 6

Ref country code: BG

Payment date: 20231117

Year of fee payment: 6

Ref country code: AT

Payment date: 20231127

Year of fee payment: 6

Ref country code: LU

Payment date: 20231214

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231121

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20231107

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240115

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20231130

Year of fee payment: 6

Ref country code: CH

Payment date: 20240101

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231215

Year of fee payment: 6

Ref country code: PL

Payment date: 20231206

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220928

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20231212

Year of fee payment: 6

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: AL

Effective date: 20221010